Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 guselkumab versus placebo in Chinese adults with moderate to severe plaque psoriasis
ChiCTR2200056656Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in plaque psoriasis comparing Guselkumab 100 mg with Placebo (2 arms). Primary endpoints: Psoriasis Area and Severity Index and Investigator's Global Assessment. Started Jan 2022; status: recruiting.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2200056656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056656.